Abstract
This case report describes the effective use of etanercept in a 63-year-old male patient with moderate to severe psoriasis and vitiligo unresponsive to local and systemic therapies. Latent tuberculosis was diagnosed at baseline and the patient was treated with isoniazid for 9 months. One month after starting isoniazid, etanercept therapy (12 weeks) for psoriasis was initiated. One month later, hepatitis B virus (HBV) markers were detected, but virological tests for active HBV were negative. Isoniazid and etanercept treatments were completed without incidence. Further clinical investigations are required to confirm the potential effects of anti-tumour necrosis factor alpha agents in such patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lawlor C, Kirby B. Neuropeptides and psoriasis. G Ital Dermatol Venereol 2007; 142: 479–88
Martin-Ezquerra G, Ferran M, Pjol RM. Update on therapeutic options for psoriasis. G Ital Dermatol Venereol 2007; 142: 547–66
Romero-Mate A, Garcia-Donoso C, Cordoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol 2007; 8: 143–55
Boehncke WH, Brasie RA, Barker J, et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006; 20: 988–98
Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766–72
Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007; 137: 620–2
Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21: 1366–71
Desai SB, Furst DE. Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20: 757–90
Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009–22
Ahmed A, Keeffe E. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol 1999; 94: 249–51
Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35: 421–4
Acknowledgments
The authors would like to thank Mary Hines of inScience Communications who provided assistance with English-language editing. This assistance was funded by Pfizer. The authors report no conflicts of interest.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Prestinari, F., Ferguglia, G. & Laria, G. Etanercept in a Patient with Severe Psoriasis and Latent Viral Hepatic Disease and Latent Tuberculosis. AM J Clin Dermatol 11 (Suppl 1), 57–58 (2010). https://doi.org/10.2165/1153429-S0-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/1153429-S0-000000000-00000